Xtandi revenue trends
In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance, which reflected ~21% growth on a YoY (year-over-year) basis and 12% growth quarter-over-quarter.
In fiscal 2017, Xtandi generated revenues of $590 million—compared to $140 million in 2016.
Xtandi (enzalutamide) is used to treat individuals with metastatic castration-resistant prostate cancer.
In February 2018, Pfizer and Astellas Pharma presented the results from the phase 3 PROSPER trial. Pfizer and Astellas Pharma conducted the phase 3 PROSPER trial to evaluate the safety and efficacy of Xtandi in individuals with non-metastatic castration-resistant prostate cancer.
According to Pfizer’s press release on February 5, 2018, “Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone. The median for the primary endpoint, metastasis-free survival (MFS), was 36.6 months for men who received XTANDI compared to 14.7 months with ADT alone.” To learn more about results of the PROSPER trial, please refer to Pfizer’s news release.
Superior data from the clinical trial are expected to boost Xtandi’s commercialization capabilities. Xtandi should receive approval from different regulatory authorities around the world.
Pfizer and Astellas Pharma have submitted regulatory applications for label expansion to the FDA and the European Medicines Agency based on the results of the PROSPER study. The approval of Xtandi’s label expansion for use in non-metastatic castration-resistant prostate cancer is expected to boost the drug’s revenue growth.